ASSESSMENT OF CUTANEOUS ADVERSE DRUG REACTIONS ASSOCIATED WITH COMMON THERAPEUTIC AGENTS
Abstract
Cutaneous adverse drug reactions (CADRs) are among the most frequently reported adverse drug reactions and represent an important clinical concern in pharmacotherapy. These reactions can range from mild skin eruptions to severe and potentially life-threatening conditions, affecting patient safety and treatment adherence. Understanding the patterns and drug classes associated with CADRs is essential for improving pharmacovigilance and ensuring safe medication use. A retrospective observational study was conducted in a tertiary care hospital to evaluate the occurrence and patterns of
CADRs. Data were collected from previously documented medical records and pharmacovigilance reports of patients diagnosed with CADRs. A total of 80 patients were included in the study. Information regarding demographic characteristics, suspected drug classes, types of cutaneous reactions, time of onset, and severity of reactions was extracted and analyzed. Descriptive statistics, including frequencies, percentages, mean, and standard deviation, were used to summarize the data, and correlation analysis was performed to examine relationships between selected clinical variables.
CADRs were observed among patients of different age groups and both genders. Antibiotics were the most frequently implicated drug class, followed by non-steroidal anti-inflammatory drugs and antiepileptic medications. Maculopapular rash was identified as the most common clinical manifestation, followed by urticaria and fixed drug eruption. The results also indicated positive associations between selected clinical variables, including age, onset time, and severity of
reactions. The study highlights the clinical significance of CADRs and the need for effective monitoring of adverse drug reactions in healthcare settings to enhance patient safety and optimize therapeutic outcomes.
Downloads
References
Adhikari, A., Bhattacharjee, N., Bhattacharya, S., Indu, R., & Ray, M. (2017). Evaluation of adverse drug reactions in
tertiary care hospital of Kolkata, West Bengal, India. Journal of Young Pharmacists, 9(3), 311.
Amalba, A., & Bugri, A. A. (2021). Assessing the prevalence and effect of adverse drug reactions among patients
receiving first line anti-tubercular medicines in the Tamale Teaching Hospital, Ghana. The Pan African Medical
Journal, 38, 191.
Bangwal, R., Bisht, S., Saklani, S., Garg, S., & Dhayani, M. (2020). Psychotic disorders, definition, sign and
symptoms, antipsychotic drugs, mechanism of action, pharmacokinetics & pharmacodynamics with side effects &
adverse drug reactions: Updated systematic review article. Journal of Drug Delivery and Therapeutics, 10(1), 163-
Benitez, L. L., & Carver, P. L. (2019). Adverse effects associated with long-term administration of azole antifungal
agents. Drugs, 79(8), 833-853.
Copaescu, A. M., & Trublano, J. A. (2022). The assessment of severe cutaneous adverse drug reactions. Australian
prescriber, 45(2), 43.
Dey, S., Luo, H., Fokoue, A., Hu, J., & Zhang, P. (2018). Predicting adverse drug reactions through interpretable deep
learning framework. BMC bioinformatics, 19(Suppl 21), 476.
Duong, T. A., Valeyrie-Allanore, L., Wolkenstein, P., & Chosidow, O. (2017). Severe cutaneous adverse reactions to
drugs. The Lancet, 390(10106), 1996-2011.
Fan, W. L., Shiao, M. S., Hui, R. C. Y., Su, S. C., Wang, C. W., Chang, Y. C., & Chung, W. H. (2017). HLA association
with drug‐induced adverse reactions. Journal of immunology research, 2017(1), 3186328.
Freites-Martínez, A., Santana, N., Arias-Santiago, S., & Viera, A. (2021). Using the common terminology criteria for
adverse events (CTCAE–version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas DermoSifiliográficas (English Edition), 112(1), 90-92.
Galli, J. A., Pandya, A., Vega‐Olivo, M., Dass, C., Zhao, H., & Criner, G. J. (2017). Pirfenidone and nintedanib for
pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions. Respirology, 22(6), 1171-1178.
Giardina, C., Cutroneo, P. M., Mocciaro, E., Russo, G. T., Mandraffino, G., Basile, G., ... & Arcoraci, V. (2018).
Adverse drug reactions in hospitalized patients: results of the FORWARD (Facilitation of Reporting in Hospital Ward)
study. Frontiers in pharmacology, 9, 350.
Gonçalves, J., Rosado, T., Soares, S., Simão, A. Y., Caramelo, D., Luís, Â., ... & Duarte, A. P. (2019). Cannabis and
its secondary metabolites: their use as therapeutic drugs, toxicological aspects, and analytical
determination. Medicines, 6(1), 31.
Mockenhaupt, M. (2017). Epidemiology of cutaneous adverse drug reactions. Allergologie select, 1(1), 96.
Muntyanu, A., Netchiporouk, E., Gerstein, W., Gniadecki, R., & Litvinov, I. V. (2021). Cutaneous immune-related
adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management. Journal of
Cutaneous Medicine and Surgery, 25(1), 59-76.
Murthy, A. B., Amuthavalli, K., Nirmaladevi, P., & Meenakshi, B. (2022). Analysis of cutaneous adverse drug
reactions in a tertiary care hospital in South Tamil Nadu. Int J Basic Clin Pharmacol, 11(2), 97-107.
Patton, K., & Borshoff, D. C. (2018). Adverse drug reactions. Anaesthesia, 73, 76-84.
Phillips, G. S., Wu, J., Hellmann, M. D., Postow, M. A., Rizvi, N. A., Freites-Martinez, A., ... & Lacouture, M. E.
(2019). Treatment outcomes of immune-related cutaneous adverse events. Journal of Clinical Oncology, 37(30),
-2758.
Ramos-Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N., Khamashta, M. A., ... & SuárezAlmazor, M. E. (2020). Immune-related adverse events of checkpoint inhibitors. Nature reviews Disease
primers, 6(1), 38.
Rimassa, L., Danesi, R., Pressiani, T., & Merle, P. (2019). Management of adverse events associated with tyrosine
kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer treatment reviews, 77, 20-
Shalayel, M. H. F., Ayed, I. A. M., Huneif, M. A., & Kordofani, Y. M. (2018). A retrospective evaluation of cutaneous
adverse drug reactions (CADRs) due to antibiotics using naranjo adverse drug reactions (ADRs) probability
scale. Journal of Young Pharmacists, 10(1), 113.
Shiohara, T., & Mizukawa, Y. (2019). Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with
eosinophilia and systemic symptoms (DRESS): an update in 2019. Allergology international, 68(3), 301-308.
Sudha, T. S., Vangoori, Y., & Varghese, A. M. (2021). A profile of adverse drug reactions in a teritiary care teaching
hospital and associated factors. Biomed. Pharm. J, 14, 367-371.
Tsegaye, M., Shimels, T., & Bilal, A. I. (2018). Prevalence of Topical Corticosteroids Related Adverse Drug Events
and Associated Factors in Selected Community Pharmacies and Cosmetic Shops of Addis Ababa, Ethiopia. Sudan
Journal of Medical Sciences, 13(1).
Wang, C. W., Yang, L. Y., Chen, C. B., Ho, H. C., Hung, S. I., Yang, C. H., ... & Chung, W. H. (2018). Randomized,
controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. The Journal of clinical
investigation, 128(3), 985-996.
Wang, D. Y., Salem, J. E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., ... & Johnson, D. B. (2018). Fatal toxic effects
associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA oncology, 4(12), 1721-
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 International Journal For Research In Biology & Pharmacy
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
In consideration of the journal, Green Publication taking action in reviewing and editing our manuscript, the authors undersigned hereby transfer, assign, or otherwise convey all copyright ownership to the Editorial Office of the Green Publication in the event that such work is published in the journal. Such conveyance covers any product that may derive from the published journal, whether print or electronic. Green Publication shall have the right to register copyright to the Article in its name as claimant, whether separately
or as part of the journal issue or other medium in which the Article is included.
By signing this Agreement, the author(s), and in the case of a Work Made For Hire, the employer, jointly and severally represent and warrant that the Article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties, and that the Article has not been published elsewhere, and is not being considered for publication elsewhere in any form, except as provided herein. Each author’s signature should appear below. The signing author(s) (and, in
